home / stock / snpx / snpx quote
Last: | $1.56 |
---|---|
Change Percent: | 15.56% |
Open: | $1.35 |
Close: | $1.56 |
High: | $1.6 |
Low: | $1.27 |
Volume: | 38,601 |
Last Trade Date Time: | 05/18/2021 04:42:35 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.56 | $1.35 | $1.56 | $1.6 | $1.27 | 38,601 | 05-18-2021 |
$1.35 | $1.31 | $1.35 | $1.44 | $1.3 | 6,878 | 05-17-2021 |
$1.28 | $1.46 | $1.28 | $1.46 | $1.25 | 46,712 | 05-14-2021 |
$1.46 | $1.36 | $1.46 | $1.52 | $1.26 | 98,074 | 05-13-2021 |
$1.43 | $1.61 | $1.43 | $1.74 | $1.205 | 252,891 | 05-12-2021 |
$1.66 | $1.74 | $1.66 | $1.75 | $1.58 | 51,204 | 05-11-2021 |
$1.75 | $1.98 | $1.75 | $1.98 | $1.54 | 88,083 | 05-10-2021 |
$2 | $2.01 | $2 | $2.14 | $1.98 | 17,092 | 05-07-2021 |
$2.0299 | $2.08 | $2.0299 | $2.2 | $1.98 | 52,482 | 05-06-2021 |
$2.2801 | $2.33 | $2.2801 | $2.33 | $2.02 | 1,381 | 05-05-2021 |
$2.15 | $2.3 | $2.15 | $2.3 | $2 | 11,119 | 05-04-2021 |
$2.16 | $2.35 | $2.16 | $2.35 | $2.1001 | 44,663 | 05-03-2021 |
$2.39 | $2.4 | $2.39 | $2.7 | $2.2499 | 121,185 | 04-30-2021 |
$2.75 | $2.64 | $2.75 | $2.75 | $2.4 | 21,746 | 04-29-2021 |
$2.7 | $2.57 | $2.7 | $2.78 | $2.52 | 49,020 | 04-28-2021 |
$2.7 | $2.6 | $2.7 | $2.74 | $2.48 | 19,977 | 04-27-2021 |
$2.69 | $2.5 | $2.69 | $2.79 | $2.32 | 20,906 | 04-26-2021 |
$2.5 | $2.5 | $2.5 | $2.5 | $2.4 | 7,729 | 04-23-2021 |
$2.47 | $2.35 | $2.47 | $2.5 | $2.3 | 3,074 | 04-22-2021 |
$2.5 | $2.35 | $2.5 | $2.5 | $2.2 | 12,335 | 04-21-2021 |
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...